ArticleThe Korean journal of internal medicine2026
Clinical outcomes of heart failure with improved ejection fraction in patients treated with angiotensin receptor-neprilysin inhibitor.
Article in The Korean journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
BACKGROUND/
aimsImprovement of left ventricular ejection fraction (LVEF) in heart failure with reduced ejection fraction (HFrEF) has been associated with favorable outcomes; however, corresponding data in patients treated with angiotensin receptor- neprilysin inhibitors (ARNIs) remain limited. This study aimed to examine the characteristics, predictors, and outcomes of HF with improved ejection fraction (HFimpEF) compared with persistent HFrEF in the RECORD-SV registry.
methodsPatients with LVEF ≤ 40% in the RECORD-SV registry were classified based on echocardiographic assessments at baseline and 1-year follow-up. Patients with HFimpEF were defined as those with follow-up LVEF of > 40% with an absolute improvement of ≥ 10%, whereas the persistent HFrEF group included those who did not meet these criteria. Baseline characteristics, predictive factors, and clinical outcomes of the patients were analyzed. The primary composite outcome was allcause mortality and hospitalization for HF management, with secondary outcomes including each component of the primary outcome and frequency of urgent emergency room visits.
resultsAmong 198 patients with HFrEF, 60 patients (30.3%) achieved HFimpEF after one year of ARNI-based therapy. Independent predictors of HFimpEF included female sex, non-ischemic etiology, and de novo HF. HFimpEF patients exhibited significantly lower risks in the primary composite outcome (HR 0.382, 95% CI 0.148-0.985) compared to those with persistent HFrEF, with a similar trend observed for secondary outcomes.
conclusionPatients achieving HFimpEF with ARNIs exhibited distinct clinical features and significantly lower risk of cardiovascular events compared to those with persistent HFrEF, highlighting the prognostic benefit of EF recovery with ARNI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.